Photo Rounds

Eyebrow hair loss

A 23-year-old woman with idiopathic peripheral neuropathy and migraine headaches messaged her primary care physician via Patient Portal regarding expanded hair loss on her left eyebrow. She reported an increase in stress due to the novel coronavirus disease (COVID-19) pandemic but denied picking at her eyebrow. She said that the skin had been feeling rough and dry for about 2 weeks and she’d noticed progressive hair loss resulting in a complete bald spot in the middle third of her left eyebrow. She denied any trauma to the area, pruritus, or erythema and reported no similar prior episodes or bald patches on her body.

What’s your diagnosis?


 

References

Eyebrow hair loss

Although it appeared that the hair loss was preceded by some dry skin, the patch of hair loss was smooth and nonscarring, consistent with a diagnosis of alopecia areata (AA).

AA typically is found on the scalp in solitary areas but can affect the whole body, including the eyelashes and eyebrows. Affected hair typically is narrower at the proximal end, resembling an exclamation point, as the hair fails to grow and falls out. Sometimes, patches of alopecia may coalesce into a larger area. Nail changes may be noted, as well. Nails may become brittle, with pitting and/or longitudinal ridges. Patients are usually asymptomatic but may complain of pruritus.

AA is believed to be an autoimmune disorder. It affects males and females of all ages but is more common in children and young adults. AA is believed to result from a T-cell–mediated immune response that transitions the hair follicles from the growth phase to the resting phase. This leads to sudden hair loss and inhibition of regrowth of the hair. However, the hair follicle is not permanently destroyed as in other processes of alopecia. There is also an association between AA and other autoimmune disorders such as vitiligo, thyroid disease, and lupus.

The diagnosis usually is made clinically, as in this patient, but a definitive diagnosis can be made by biopsy and pathology. Other differential diagnoses to consider are trichotillomania, tinea, traumatic alopecia, and lupus.

In almost half of cases, AA is self-resolving; therefore, in first episodes of localized disease, watchful waiting is appropriate. Treatment is tailored to the individual patient and may be difficult. Intralesional corticosteroids often are used for mild cases. Typically, 10 mg/mL of a glucocorticoid is injected into the mid-dermis every 4 to 6 weeks; however, this treatment carries a risk of transient or even permanent atrophy of the injection site. Potent topical corticosteroids often are used, especially in children who do not tolerate intralesional injections, and success can be variable. Other topical treatments to consider are photochemotherapy (psoralen plus UVA), or an irritant agent such as anthralin and a vasodilator such as minoxidil. Regrowth can be expected in a few months to a year, but recurrence is common.

Image courtesy of Stacy Nguy, MD, and text courtesy of Stacy Nguy, MD, and Daniel Stulberg, MD, FAAFP, Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque.

Recommended Reading

Hair loss and scalp papules
Clinician Reviews
Review finds evidence for beta-blockers for some rosacea symptoms
Clinician Reviews
Pregnancy studies on psoriasis, PsA medications pick up
Clinician Reviews
Study highlights differences between White and Latino patients with psoriasis
Clinician Reviews
Expert spotlights recent advances in the medical treatment of acne
Clinician Reviews
Don’t discount ultrapotent topical corticosteroids for vulvar lichen sclerosus
Clinician Reviews
Chronic, nonhealing leg ulcer
Clinician Reviews
Rapidly developing vesicular eruption
Clinician Reviews
Was This Tattoo a Rash Choice?
Clinician Reviews
Baricitinib reduces adult atopic dermatitis severity in phase 3 study
Clinician Reviews